Allergan Aesthetics presents data on Medical Weight Loss (MWL)

Allergan Aesthetics has recently unveiled compelling new data on Medical Weight Loss (MWL) treatments and how they are reshaping patient behavior and aesthetic demands. This shift in trend has shed light on the evolving landscape of aesthetic care, highlighting the increasing importance of facial volume restoration and patient consultation strategies.

According to the data, a significant 67% of patients undergoing MWL treatments have reported a change in their appearance goals, emphasizing an interest in improving their overall aesthetic rather than solely focusing on weight reduction. Moreover, health care providers (HCPs) have identified that almost half of MWL patients (47%) have benefitted the most from hyaluronic acid injectable fillers, particularly in addressing post-weight loss facial concerns. This data underscores how MWL treatments have sparked a change in patients’ aesthetic priorities.

The evolving demand for specific treatments within the MWL patient population has also brought to light the crucial role that facial volume restoration plays in providing patients with balanced and natural-looking outcomes. Patients undergoing rapid weight loss often experience visible changes in their facial structure, making early consultation and proactive treatment planning essential to guide them through their transformation journey effectively.

Interestingly, the data reveals that aesthetic practices are increasingly becoming the point of entry for MWL patients considering professionally administered aesthetic treatments. With 60% of consumers receiving GLP-1 medications from healthcare providers who also offer aesthetic treatments, the synergy between MWL and aesthetic care is becoming more apparent. This integration has led to a surge in consumer interest in aesthetics, with a significant portion of MWL patients exploring aesthetic treatments in physician’s offices or medspas.

Physicians and experts in the field have reported a notable shift in patient demands following MWL treatments, with facial volume loss emerging as the primary concern among GLP-1 patients. Key findings suggest that hyaluronic acid dermal fillers are a popular treatment choice among HCPs, identified as a top nonsurgical modality post-GLP-1 related weight loss. The data further indicates an overall increase in the volume of dermal filler injections in practices, emphasizing the growing impact of MWL on aesthetic care trends.

As Allergan Aesthetics continues to delve into the intersection of MWL and aesthetic medicine, their commitment to providing healthcare providers with data-driven insights remains unwavering. Through extensive consumer research, collaboration with physicians, and participation in medical forums, the company aims to translate emerging trends into actionable insights that can guide healthcare providers in meeting the evolving needs of MWL patients seeking aesthetic solutions.